Piper Jaffray Companies restated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Monday, December 16th, Stock Target Advisor reports. The brokerage currently has a $104.00 price target on the stock.
Other equities research analysts have also issued reports about the stock. Chardan Capital reaffirmed a buy rating and set a $72.50 price objective on shares of Crispr Therapeutics in a report on Monday, November 18th. Goldman Sachs Group increased their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a report on Tuesday, November 19th. Wells Fargo & Co restated a buy rating on shares of Crispr Therapeutics in a report on Friday, December 6th. TheStreet raised shares of Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. Finally, BidaskClub cut Crispr Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, December 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company. Crispr Therapeutics currently has an average rating of Buy and an average target price of $71.38.
CRSP traded down $0.94 during trading on Monday, reaching $60.91. 1,392,928 shares of the company traded hands, compared to its average volume of 979,781. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 12-month low of $27.11 and a 12-month high of $74.00. The firm has a fifty day simple moving average of $65.80 and a 200 day simple moving average of $50.98. The company has a market cap of $3.36 billion, a P/E ratio of -17.70 and a beta of 3.31.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. As a group, sell-side analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,118 shares of company stock worth $3,620,760. Company insiders own 21.40% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Benjamin Edwards Inc. grew its stake in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after purchasing an additional 268 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Crispr Therapeutics by 13.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after buying an additional 343 shares during the period. Traynor Capital Management Inc. lifted its holdings in shares of Crispr Therapeutics by 5.8% in the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after buying an additional 375 shares during the period. Commonwealth Equity Services LLC grew its position in shares of Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after buying an additional 386 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Crispr Therapeutics by 7.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after buying an additional 467 shares in the last quarter. Institutional investors and hedge funds own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is Depreciation?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.